Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-D computed tomography volumetry

Clinical Breast Cancer

Volumn 14, Issue 5, 2014, Pages 365-370

  Battisti, Sofia ^a   Guida, Francesco Maria ^a   Coppa, Federica ^a   Vaccaro, Donata M ^a   Santini, Daniele ^a   Tonini, Giuseppe ^a   Zobel, Bruno B ^a   Semelka, Richard C ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase inhibitor therapy; Breast cancer; CT; Subcutaneous fat; Visceral fat

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; LETROZOLE;

ABDOMINAL FAT; ABDOMINAL SUBCUTANEOUS FAT; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY FAT DISTRIBUTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGING SOFTWARE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; MIDDLE AGED; POSTMENOPAUSE; THREE DIMENSIONAL IMAGING; TOTAL ABDOMINAL ADIPOSE TISSUE; TREATMENT OUTCOME; VISCERAL ADIPOSE TISSUE SUBCUTANEOUS ADIPOSE TISSUE RATIO; VOLUMETRY; BREAST NEOPLASMS; DRUG EFFECTS; RADIOGRAPHY; SUBCUTANEOUS FAT;

AROMATASE INHIBITORS; BODY FAT DISTRIBUTION; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; INTRA-ABDOMINAL FAT; MIDDLE AGED; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84922647522     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.02.003     Document Type: Article

References (42)

1. Daudt A, Alberg AJ, Helzlsouer KJ. Epidemiology, prevention, and early detection of breast cancer. Curr Opin Oncol 1996; 8:455-61.
2. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-18.
3. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006; 102:89-96.
4. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw 2005; 3:309-14.
5. Labrie F, Simard J, Luu-The V, Pelletier G, Belghmi K, Belanger A. Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 betahydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. Baillieres Clin Endocrinol Metab 1994; 8:451-74.
6. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24:152-82.
7. Desta Z, Nguyen A, Flockhart D, et al. Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics 2009; 19:554-5.
8. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and metaanalysis. J Natl Cancer Inst 2011; 103:1299-309.
9. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-96.
10. Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol 2009; 472:57-88.
11. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010; 11:11-8.
12. Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004; 113: 1530-2.
13. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3:35-42.
14. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697-738.
15. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 2002; 34:616-21.
16. Korhonen S, Hippelainen M, Vanhala M, Heinonen S, Niskanen L. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 2003; 79: 1327-34.
17. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgenestrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990; 70:473-9.
18. Simpson ER. Genetic mutations resulting in loss of aromatase activity in humans and mice. J Soc Gynecol Investig 2000; 7(suppl 1):S18-21.
19. Jones ME, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice accumulate excess adipose tissue. J Steroid Biochem Mol Biol 2001; 79:3-9.
20. Jones ME, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 2000; 97:12735-40.
21. Blanchette S, Blouin K, Richard C, Dupont P, Luu-The V, Tchernof A. Expression and activity of 20alpha-hydroxysteroid dehydrogenase (AKR1C1) in abdominal subcutaneous and omental adipose tissue in women. J Clin Endocrinol Metab 2005; 90:264-70.
22. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88:2404-11.
23. Hirooka M, Kumagi T, Kurose K, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med 2005; 44:794-9.
24. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999; 211:283-6.
25. Kuk JL, Church TS, Blair SN, Ross R. Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome? Diabetes Care 2006; 29:679-84.
26. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982; 36:172-7.
27. Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes Res 1996; 4:201-3.
28. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493-6.
29. Bjorntorp P. Regional patterns of fat distribution. Ann Int Med 1985; 103:994-5.
30. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992; 55:950-4.
31. Kotani K, Tokunaga K, Fujioka S, et al. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int J Obes Relat Metab Disord 1994; 18:207-2.
32. Artac M, Bozcuk H, Afacan B, Ozdogan M, Samur M. The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors. Breast 2008; 17:418-22.
33. Rice S, Patel B, Bano G, Ugwumadu A, Whitehead SA. Aromatase expression in abdominal omental/visceral and subcutaneous fat depots: a comparison of pregnant and obese women. Fertil Steril 2012; 97:1460-1466.e1.
34. Poehlman ET. Re: Tchernof, A. and Poehlman E., Effects of the menopause transition on body fatness and body fat distribution, Obesity Research vol. 6, No. 3 (May):246-254 1998.
35. Obes Res 2005; 13:1300.
36. Engan T, Krane J, Johannessen DC, Lonning PE, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapyelipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995; 36: 287-97.
37. Kim KR, Chung HC, Lee E, Kim SJ, Namkoong K. Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Support Care Cancer 2012; 20:2177-82.
38. Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 2009; 150:2537-42.
39. Santen RJ. Assessing individual risk for breast cancer: role of oestrogens and androgens. Breast Cancer Res 2008; 10(suppl 4):S10.
40. Lapauw B, T'Sjoen G, Mahmoud A, Kaufman JM, Ruige JB. Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men. Eur J Endocrinol 2009; 160:397-402.
41. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-29.
42. Noone TC, Semelka RC, Chaney DM, Reinhold C. Abdominal imaging studies: comparison of diagnostic accuracies resulting from ultrasound, computed tomography, and magnetic resonance imaging in the same individual. Magn Reson Imaging 2004; 22:19-24.